Managing side effects in adjuvant endocrine therapy for breast cancer. Issue 11 (2nd November 2018)

• Record Type: Journal Article
• Authors: Condorelli, Rosaria; Vaz-Luis, Ines
• Is Part Of: Expert review of anticancer therapy. Volume 18:Issue 11(2018)
• Page Start: 1101
• Page End: 1112
• Publication Date: 2018-11-02
• Subjects: Early breast cancer -- endocrine therapy -- vasomotor symptoms -- musculoskeletal symptoms -- vulvovaginal symptoms; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1080/14737140.2018.1520096
• Languages: English
• ISSNs: 1473-7140

Abstract

ABSTRACT: Introduction : Recent improvements in the survival of hormone-responsive breast cancer are strongly associated with therapeutic advances, particularly with the uptake of adjuvant endocrine therapy. Nevertheless, endocrine therapy is also linked with adverse effects that impact quality of life, social function, and adherence to treatment. Areas covered : This review examines the spectrum and consequences of adverse effects of tamoxifen and aromatase inhibitors, and the pharmacological and non-pharmacological approaches to mitigate some of the most frequent and disturbing side effects of endocrine therapy (including vasomotor, musculoskeletal, and vulvovaginal symptoms). The authors performed a qualitative analysis of English papers indexed in PubMed through May 2017, including meta-analysis, randomized controlled trials, observational studies, and systematic reviews. Expert commentary : Side effects of endocrine treatments are frequent and often underestimated in the care of breast cancer survivors, leading to a poor adherence to treatments that can compromise oncological outcomes. Many of the most common adverse events can be mitigated through pharmacological and non-pharmacological approaches that should be discussed and offered to patients in a dedicated setting of care.